9.38
1.79%
+0.165
After Hours:
9.36
-0.02
-0.21%
Verastem Inc stock is currently priced at $9.38, with a 24-hour trading volume of 42,668.
It has seen a +1.79% increased in the last 24 hours and a -19.07% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $9.21 pivot point. If it approaches the $9.39 resistance level, significant changes may occur.
Previous Close:
$9.215
Open:
$9.23
24h Volume:
42,668
Market Cap:
$237.39M
Revenue:
$3.64M
Net Income/Loss:
$-87.37M
P/E Ratio:
-2.1465
EPS:
-4.37
Net Cash Flow:
$-86.46M
1W Performance:
-4.67%
1M Performance:
-19.07%
6M Performance:
+38.96%
1Y Performance:
+2,409%
Verastem Inc Stock (VSTM) Company Profile
Name
Verastem Inc
Sector
Industry
Phone
781-292-4200
Address
117 Kendrick Street, Suite 500, Needham, MA
Verastem Inc Stock (VSTM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-07-22 | Resumed | Alliance Global Partners | Buy |
Apr-29-22 | Resumed | Cantor Fitzgerald | Overweight |
Apr-14-22 | Initiated | RBC Capital Mkts | Outperform |
Mar-09-22 | Initiated | Truist | Buy |
Jul-01-21 | Initiated | Alliance Global Partners | Buy |
May-24-21 | Upgrade | BTIG Research | Neutral → Buy |
Jun-20-19 | Downgrade | BTIG Research | Buy → Neutral |
May-10-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
Jul-13-18 | Initiated | BTIG Research | Buy |
May-02-18 | Initiated | Seaport Global Securities | Buy |
Mar-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
Sep-07-17 | Reiterated | H.C. Wainwright | Buy |
Apr-13-17 | Initiated | Oppenheimer | Outperform |
Mar-24-17 | Reiterated | H.C. Wainwright | Buy |
Sep-29-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
Sep-29-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Sep-29-15 | Downgrade | Jefferies | Buy → Hold |
Sep-29-15 | Downgrade | Raymond James | Strong Buy → Outperform |
Sep-28-15 | Downgrade | Mizuho | Buy → Neutral |
Sep-28-15 | Downgrade | ROTH Capital | Buy → Neutral |
Sep-09-15 | Initiated | Raymond James | Strong Buy |
May-12-15 | Reiterated | UBS | Buy |
Apr-08-15 | Initiated | H.C. Wainwright | Buy |
Jan-23-15 | Reiterated | ROTH Capital | Buy |
Jul-08-14 | Resumed | Oppenheimer | Perform |
Feb-11-14 | Initiated | Mizuho | Buy |
View All
Verastem Inc Stock (VSTM) Latest News
Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy
Zacks Investment Research
All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy
Zacks Investment Research
Where Verastem Stands With Analysts
Benzinga
Verastem: Potential Accelerated Approval Filing In H1 2024
Seeking Alpha
Verastem Inc Stock (VSTM) Financials Data
Verastem Inc (VSTM) Revenue 2024
VSTM reported a revenue (TTM) of $3.64 million for the quarter ending March 31, 2022.
Verastem Inc (VSTM) Net Income 2024
VSTM net income (TTM) was -$87.37 million for the quarter ending December 31, 2023, a -18.36% decrease year-over-year.
Verastem Inc (VSTM) Cash Flow 2024
VSTM recorded a free cash flow (TTM) of -$86.46 million for the quarter ending December 31, 2023, a -35.79% decrease year-over-year.
Verastem Inc (VSTM) Earnings per Share 2024
VSTM earnings per share (TTM) was -$4.11 for the quarter ending December 31, 2023, a +9.87% growth year-over-year.
About Verastem Inc
Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. The company is also developing a dual inhibitor of PI3K-delta and PI3K-gamma, which has completed Phase 2 study in indolent non-hodgkin lymphoma. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd. and The Leukemia & Lymphoma Society. The company was founded in 2010 and is headquartered in Needham, Massachusetts.
Cap:
|
Volume (24h):